Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05678998 · ClinicalTrials.gov registry record · Phase 1
WTX-330 in Patients With Advanced or Metastatic Solid Tumors or Non-Hodgkin Lymphoma
A Phase 1 study, sponsored by Werewolf Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 25
- Enrollment target
NCT05678998: Completed Phase 1 study, sponsored by Werewolf Therapeutics.
NCT05678998 is a Phase 1 study that has completed, run by Werewolf Therapeutics. The registered enrollment target is 25 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (58% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05678998, a Phase 1 study, has completed, sponsored by Werewolf Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 25 participants
- Enrollment target
Study Summary
A first-in-human, Phase 1, open-label, multicenter study of WTX-330 administered as a monotherapy to patients with advanced or metastatic solid tumors or non-Hodgkin lymphoma.
Primary Outcome
A DLT is defined as an AE or abnormal laboratory value assessed as unrelated to disease, disease progression, intercurrent illness, or concomitant medications that occurs within the first cycle of treatment with WTX-330 and meets any of the criteria included in the protocol
Interventions
- DRUG WTX-330
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2022-12-06 |
| Est. Completion | 2025-02-05 |
| Phase | Phase 1 |
What the finished NCT05678998 record still lists
NCT05678998 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 25 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (58% lower).
The record links to 0 conditions, and to 1 intervention - of which WTX-330 is the first listed.
NCT05678998 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05678998 about?
NCT05678998 is a clinical study titled "WTX-330 in Patients With Advanced or Metastatic Solid Tumors or Non-Hodgkin Lymphoma". A first-in-human, Phase 1, open-label, multicenter study of WTX-330 administered as a monotherapy to patients with advanced or metastatic solid tumors or non-Hodgkin lymphoma.
What is the current status of trial NCT05678998?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 25 participants. The study started on 2022-12-06. Estimated completion is 2025-02-05.
What interventions are being tested in trial NCT05678998?
The interventions under investigation include: WTX-330 (DRUG).
Who is sponsoring clinical trial NCT05678998?
This trial is sponsored by Werewolf Therapeutics, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05678998's enrollment target sits among peer trials
25 1495th of 2000 higher than 481 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01166854 · 25 participants
Characterization of Familial Myopathy and Paget Disease of Bone
- NCT01913106 · 25 participants · Phase 1
HSV-tk + Valacyclovir Therapy in Combination With Brachytherapy for Recurrent Prostate Cancer
- NCT02138669 · 25 participants · NA
Intacs Prescription Inserts for Keratoconus Patients
- NCT02174549 · 25 participants · Phase 1
Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI